I do not agree. The ISIS panel review indicated a likelyhood of strong restrictions by the FDA on the ISIS drug that will position AEGR to take a vastly disproportionate marketshare. That is why ISIS took such a big hit (down 33%-40%) on the news. AEGR should have surged far more so for the same reason. This will come to fruition in time once people realize the magnitude of the situation.